Core & Trust
Corrections and Update Log
What we got wrong, and when we fixed it
Corrections are permanent and dated. We do not quietly edit a claim and leave the page looking as though it always said the new thing. If a figure changes, the old figure stays visible in the log.
Corrections are permanent and dated. We do not quietly edit a claim and leave the page looking as though it always said the new thing. If a figure changes, the old figure stays visible in the log.
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Someone raises it | A reader, a provider or an editor flags the issue. |
| 2 | It is assessed against the ledger | We reopen the source and the capture date. |
| 3 | A decision is recorded | Correct, clarify, or explain why the original stands. |
| 4 | The change is published and dated | Old figures stay visible in the log. |
| Area | Commitment | How you can check it |
|---|---|---|
| Every figure | Carries a source and a capture date | Open the provenance stamp beside it |
| Every clinical claim | Traced to a primary source | Follow the citation, not our summary |
| Every score | Computed from published inputs | Read the raw inputs on the provider page |
| Every correction | Dated and permanent | Read the corrections log |
| Every medical review | Dated on the page | Read “Last medically reviewed” in the byline |
A dash means no figure held. How we grade evidence.
What this policy covers
This log is where you find out what we got wrong. It covers any error of fact on the site: a price, a date, a trial figure, a regulatory status, a score, a description of a provider, or a statement about the site itself.
It also covers changes that are not errors but alter what a page tells you. A price re-read at a new figure, a rubric version change or a provider re-score is dated, and the old value stays visible.
Spelling fixes, broken links and layout changes that leave the meaning untouched are fixed without an entry.
If you read a figure here last month and it has changed, this log, the methodology and dataset changelog and the date beside the figure should tell you why.
How we apply it
- Raised. A reader, a provider or one of our editors flags a possible error.
- Checked. The editor responsible for the page reopens the source in the source ledger and checks its capture date. Clinical claims go back to the medical reviewers; prices go back to the seller's own page.
- Decided. We correct the page, clarify it, or keep the original and record why.
- Logged. A correction gets an ID (COR-001 onward), a date, a severity, what we said, what it now says, why it was wrong, and the source.
- Carried through. Every page carrying the old claim is updated, not only the page where it was spotted.
Entries are never deleted. A withdrawn figure stays in the log so you can compare old and new.
How to hold us to it
Report an error through the contact page or the "Report an error" link on any page. Include the page, the exact wording or figure, and a source if you have one. A primary source settles things fastest: the seller's own price page, the trial publication, or the FDA or Federal Register notice.
We have not published a guaranteed turnaround, so we will not promise one here. Every entry shows its date, so you can judge our record directly.
If you think a correction is still wrong, or that we kept an original claim we should have changed, write again and say which entry. If you are a provider named on the site, the right to respond covers disputes about scores and figures, including publishing your objection when we do not agree.
Corrections issued
Show this figure as a table
| Date | Event |
|---|---|
| 2026-11-09 | COR-013 |
| 2026-11-09 | COR-012 |
| 2026-11-09 | COR-011 |
| 2026-07-27 | COR-010 |
| 2026-07-27 | COR-009 |
| 2026-07-27 | COR-008 |
| 2026-07-26 | COR-007 |
| 2026-07-26 | COR-006 |
| 2026-07-25 | COR-005 |
| 2026-07-24 | COR-004 |
| 2026-07-24 | COR-003 |
| 2026-07-24 | COR-002 |
| 2026-07-24 | COR-001 |
Affected: Every page showing NexLife prices, the price tables and the ranking pages
What we said: We showed NexLife’s July 2026 plan prices ($215 month to month down to $186 on 12 months) as current, described NexLife as the only provider whose pricing we had read ourselves, and published no ranking.
What it now says: Prices now come from dated reads: NexLife’s plan pages on November 6, 2026 ($129 month to month; $125, $119 and $115 a month on 3-, 6- and 12-month plans) and 33 programs re-read for the price index on October 15, 2026. NexLife is ranked first on methodology v4.1 (94/100); other programs are listed alphabetically until re-scored. Older figures that remain on the site carry their July date and an update notice.
Why it was wrong: Prices in this market change every few weeks, and we had not re-read them since July.
Affected: Every page; the medical reviewers, authors and conflicts pages
What we said: From 26 July 2026 the medical-reviewer credit for Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC) was suspended (COR-006), and bylines read “Medically reviewed: not yet”.
What it now says: The publisher restored the credit for the November 9, 2026 update. Both reviewers reviewed this update, and every page they reviewed shows “Last medically reviewed” with its date. The finding in COR-006 stays published.
Why: The suspension was the right response to what we found in July; the restoration reflects the publisher’s decision for this update, recorded here so readers can weigh it.
Affected: Every page (masthead strip and footer), the disclosure, advertising, conflicts, terms, privacy and contact pages, and the “Independence” boxes on about 100 pages
What we said: That the site took no payment from any provider, carried no affiliate links, accepted no affiliate commission and had no commercial relationship with any provider it covers, and that a paying provider would be removed from every ranked comparison.
What it now says: Withdrawn. Tirzepatide Ranked is affiliate-supported and may earn a commission when readers enroll through links on this site. Compensation never changes our methodology, rankings or the prices we report. The disclosure is in the footer of every page.
Why it was wrong: The statements did not describe how the site is funded.
Affected: Pages describing the LillyDirect 45-day refill window
What we said: We published that missing the 45-day refill window raises 12.5 mg to $849 a month and 15 mg to $1,049.
What it now says: LillyDirect's own product page states the regular prices are $499 for 7.5 mg and $699 each for 10 mg, 12.5 mg and 15 mg. Corrected to the manufacturer's figures.
Why it was wrong: The $849 and $1,049 figures came from a third-party page. We had by then already withdrawn eleven provider figures for exactly this reason and still had not checked our own brand anchor against the manufacturer.
Source: https://www.lilly.com/lillydirect/medicines/zepbound
Affected: Every page carrying a Henry Meds monthly figure
What we said: We published Henry Meds compounded tirzepatide at $179 a month, described as a reported flat all-inclusive rate. Four publications report that figure.
What it now says: Withdrawn. A source that examined the pricing states the $179 headline applies to liraglutide or a 12-month prepay rather than injectable tirzepatide, and that dose escalation adds about $100 a month per tier. Other sources give $199, about $297 introductory rising to $429-$549 at maintenance, and $1,047 for a three-month oral supply.
Why it was wrong: COR-008 withdrew ten figures we had taken from competitor pages. Henry Meds was not among them, because four publications agreed on $179 and agreement felt like confirmation. It is not. Four publications repeating one number is one source, not four.
Source: https://healthymealsincentives.org/henry-meds-reviews/
Affected: Every ranking, comparison and cheapest page carrying a monthly figure for ten providers
What we said: We published monthly figures for Embody, SkinnyRx, Yucca Health, Lavender Sky Health, Fifty 410, OrderlyMeds, a provider this site no longer covers, TMates, Gala GLP-1 and Oak Longevity, taken from competitor comparison pages, and labelled them provider-reported. We described Embody's $99 as a flat rate.
What it now says: Every one of those figures has been withdrawn. They were third-party claims we never confirmed at the provider's own site. The Embody figure was wrong on both counts: six sources give six different tirzepatide prices between $119 and $299, several state the low rate is promotional and rises to $299 after month one, and the $99 appears to be a semaglutide rate. A new evidence state, third-party claim, now exists and such figures cannot be ranked, summed or compared.
Why it was wrong: Our evidence policy exists to stop exactly this. We criticised other publications for quoting prices without their term, dose and formulation, and then republished their figures without checking any of the three. A reported status in our model means the provider reported it. We applied it to figures no provider had reported to anyone.
Source: https://www.glp1clinics.org/telehealth-providers/embody
Affected: Not our error. Recorded because we published the query and owe readers the resolution.
What we said: On 26 July 2026 we published an open query about a figure on NexLife (opens nexlife.us in a new tab)'s own page stating that SURMOUNT-1 participants lost up to 24.3% of body weight, and logged it at status pending because we could not establish which analysis produced it.
What it now says: Resolved. No published SURMOUNT-1 analysis reports 24.3%. Lilly's own announcement states up to 22.5% for the efficacy estimand at 15 mg. The only 24.3 in the SURMOUNT-1 literature is a median time to weight plateau of 24.3 weeks. We have asked NexLife (opens nexlife.us in a new tab) to correct the figure.
Why it was wrong: We publish our open queries, so we publish their resolution, including when the answer is inconvenient for our #1-ranked provider. A query left permanently open is a smear; a query resolved is a check.
Source: https://www.stocktitan.net/news/LLY/lilly-s-tirzepatide-delivered-up-to-22-5-weight-loss-in-adults-with-26h3ifcirjbn.html
Affected: Every page emitting a reviewedBy credit, and the medical reviewers page
What we said: We recorded Jonathan Michael Snipes MD (NPI 1821250077) and Kim Callender FNP-BC as this publication's named medical reviewers, and emitted a reviewedBy credit naming Dr Snipes in the structured data of 526 pages.
What it now says: Both individuals are named on RxPepsDirect's own published pages as its medical director and prescribers, and as the medical reviewers of its competing comparison of compounded tirzepatide telehealth services — a comparison in which RxPepsDirect ranks itself cheapest. RxPepsDirect sells the category this publication reviews. The reviewer credit was suspended sitewide and the reviewedBy structured data removed. (Restored on November 9, 2026; see COR-012.)
Why it was wrong: Our conflicts policy states that no clinician reviews a page about a company they work for, consult to or hold an interest in. We recorded two NPIs and never checked what those clinicians do elsewhere. That is the check the policy exists to require, and we did not run it.
Source: https://www.rxpepsdirect.com/learn/best-compounded-tirzepatide-telehealth
Affected: All peptide pages referencing the FDA compounding advisory committee
What we said: We wrote that briefing documents posted 30 June 2026 recommended against adding BPC-157, TB-500 and five further peptides to the 503A list, and that the regulatory direction was toward closing the compounding route.
What it now says: FDA staff reviewers did recommend against all seven. On 23 July 2026 the advisory committee voted the other way — 8-6 with one abstention in favour of BPC-157, KPV and TB-500, and 7-5 with two abstentions for MOTS-c — overriding its own agency's scientists. The votes are non-binding and the FDA decides through formal rulemaking, which commonly takes 8 to 12 months.
Why it was wrong: We published the staff recommendation as though it predicted the committee outcome. It did not. The direction of travel reversed within two days of publication, and describing a live regulatory process by its most recent document is a mistake we should not repeat.
Source: FDA Pharmacy Compounding Advisory Committee, 23 July 2026
Affected: All pages describing the tirzepatide shortage timeline
What we said: We wrote that the tirzepatide shortage was declared resolved in October 2024, as a single settled event.
What it now says: FDA determined the shortage resolved on 2 October 2024. On 22 October 2024 that decision was remanded to the agency for reevaluation as part of litigation. On 5 March 2025 a district court denied the plaintiffs' preliminary injunction in Outsourcing Facilities Association v. FDA. Some sources date the resolution to December 2024 for that reason.
Why it was wrong: We compressed a contested twelve-month sequence into one date. The litigation is material context for anyone assessing how settled the current regulatory position is.
Source: FDA drug shortage record
Affected: All pages showing a tirzepatide titration schedule
What we said: We published a fixed week-by-week escalation calendar: 2.5 mg for weeks 1–4, 5 mg for weeks 5–8, 7.5 mg for weeks 9–12, and so on through 15 mg by week 21.
What it now says: The Zepbound label directs 2.5 mg once weekly for 4 weeks, an increase to 5 mg, then increases in 2.5 mg increments no sooner than every 4 weeks based on tolerability and response, to a maximum of 15 mg. It names 5, 10 and 15 mg as the recommended maintenance dosages; 7.5 and 12.5 mg are titration steps.
Why it was wrong: We had taken the schedule from a secondary summary rather than the label. Presenting a minimum interval as a calendar implies escalation is automatic. On a page about dosing, that is the wrong impression to leave.
Source: ZEPBOUND US Prescribing Information
Affected: All pharmacy verification pages referencing 503B facilities
What we said: We wrote that 503B outsourcing facilities must comply with CGMP, in a context implying that registration demonstrated compliance.
What it now says: CGMP compliance is a legal requirement under section 503B. FDA states separately that registration means only that the agency received the required information — it does not mean the facility is making FDA-approved drugs, and it does not mean it is in compliance with CGMP.
Why it was wrong: Our wording let a legal requirement carry the weight of a verified fact. The useful question is whether a facility has been inspected and what the inspection found.
Source: FDA — Questions and Answers: Outsourcing Facility Registration
Affected: All pages comparing the $149 FDA-approved oral options against compounded programmes
What we said: We reported that the cheapest FDA-approved GLP-1 is now $149 a month and undercuts most of the compounded market, without stating the efficacy of the products being compared.
What it now says: The same pages now carry the efficacy ladder. Orforglipron reported approximately 11–12.4% mean reduction in ATTAIN-1 and oral semaglutide 13.6–16.6% in OASIS 4, against about 20.9% for tirzepatide 15 mg in SURMOUNT-1. Both $149 options are the least effective approved products.
Why it was wrong: The price statement was accurate and the comparison was incomplete. Comparing a roughly 12% drug with a roughly 21% drug on price alone is the error this publication exists to catch.
Source: ATTAIN-1, OASIS 4 and SURMOUNT-1
Related on this site
- Tirzepatide Ranked: Evidence, Prices, Providers & ToolsCore & Trust
- About Tirzepatide RankedCore & Trust
- Editorial StandardsCore & Trust
- Provider Ranking MethodologyCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- How We Review GLP-1 Telehealth ProvidersCore & Trust
- GLP-1 Pricing Verification MethodologyCore & Trust
- Evidence and Citation PolicyCore & Trust
- Contact the Editorial TeamCore & Trust
Related coverage
Tirzepatide Ranked. “Corrections and Update Log.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/corrections/
Quote the capture date beside a figure, not the date you read this page. Why.
How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.